Preprint · CC-BY
via OpenAlex
Proteomic Age Acceleration in Multiple Sclerosis Precedes Symptom Onset and Associates with Severity
Fatemeh Siavoshi, Julián Candia, Dimitrios C. Ladakis, Blake E. Dewey, Angeliki G. Filippatou, Matthew D. Smith, Elias S. Sotirchos, Shiv Saidha, Jerry L. Prince, Ahmed Abdelhak, Ellen M. Mowry, Peter A. Calabresi, Keenan A. Walker, Kathryn C. Fitzgerald, Pavan Bhargava
medRxiv · 2026 · ▲ 1 citations
Abstract
Abstract Biological aging is accelerated in people with multiple sclerosis, but whether such acceleration occurs during the pre-symptomatic phase or varies by organ system is understudied. We analyzed two independent proteomics datasets profiled using distinct platforms: the Johns Hopkins cohort profiled using the SomaScan platform (348 multiple sclerosis/49 age-matched controls) and the Department of Defense cohort profiled using the Olink platform (134 multiple sclerosis/79 age-matched controls), including 117 pre-symptomatic samples from people with multiple sclerosis (median lead time: 4.0 years), to estimate systemic and organ-specific proteomic age gaps using established clocks in pre-symptomatic and symptomatic phases, and assess their associations with severity. In the Johns Hopkins cohort, people with multiple sclerosis demonstrated acceleration of systemic (β=2.2, 95% CI 1.2–3.2, P <0.001, FDR<0.001), brain (β=1.7, 95% CI 0.6–2.7, P =0.003, FDR=0.01), muscle (β=2.5, 95% CI 1.3–3.7, P <0.001, FDR<0.001), and immune age (β=1.8, 95% CI 0.6–2.9, P =0.003, FDR=0.01), with findings reproduced in the Department of Defense cohort for systemic (β=0.7, 95% CI 0.0–1.4, P =0.04, FDR=0.34) and brain age (3.2 years, 95% CI 2.1–4.3, P <0.001, FDR<0.001). Proteomic age acceleration was evident prior to symptom onset [systemic: (β=1.0, 95% CI 0.4–1.7, P =0.002, FDR=0.02); brain: (β=2.4, 95% CI 1.2–3.7, P <0.001, FDR=0.002)], whereas no immune age acceleration was detected before or after onset. Higher systemic age gap was associated with greater global Age-Related Multiple Sclerosis Severity Score (β=0.14, 95% CI 0.05–0.24, P =0.005, FDR=0.03) and slower walking speed (β=0.02, 95% CI 0.01–0.03, P =0.006, FDR=0.04), while higher muscle age gap was associated with greater global Age-Related Multiple Sclerosis Severity Score (β=0.17, 95% CI 0.10–0.24, P <0.001, FDR<0.001), poorer manual dexterity (β=0.28, 95% CI 0.04–0.52, P =0.03, FDR=0.30), slower walking speed (β=0.02, 95% CI 0.01–0.03, P =0.002, FDR=0.02), lower peripapillary retinal nerve fiber layer (β= −0.26, 95% CI −0.41 to −0.10, P =0.001, FDR=0.02) and ganglion cell-inner plexiform layer thicknesses (β= −0.35; 95% CI −0.65 to −0.05; P =0.02, FDR=0.30). Higher brain age gap was associated with several imaging measures, including lower whole-brain (β= −0.002, 95% CI −0.003 to −0.001, P =0.002, FDR=0.02), and lower peripapillary retinal nerve fiber layer thickness (β= −0.21, 95% CI −0.39 to −0.03, P =0.02, FDR=0.10). Proteomic age acceleration in multiple sclerosis is detectable years before symptom onset and distinct organ-specific aging signatures are associated with disease severity. Proteomic aging may provide a biologically informative marker of early disease processes and a clinically relevant readout of disease heterogeneity.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.64898/2026.04.13.26350634
- Canonical
- link ↗
- Fetched
- 2026-11-16 MST
Cite this
APA
Siavoshi, F., Candia, J., Ladakis, D.C., Dewey, B.E., Filippatou, A.G., Smith, M.D., Sotirchos, E.S., Saidha, S., Prince, J.L., Abdelhak, A., Mowry, E.M., Calabresi, P.A., Walker, K.A., Fitzgerald, K.C., & Bhargava, P. (2026). Proteomic Age Acceleration in Multiple Sclerosis Precedes Symptom Onset and Associates with Severity. <em>medRxiv</em>. https://doi.org/10.64898/2026.04.13.26350634
Vancouver
Siavoshi F, Candia J, Ladakis DC, Dewey BE, Filippatou AG, Smith MD, et al. Proteomic Age Acceleration in Multiple Sclerosis Precedes Symptom Onset and Associates with Severity. medRxiv. 2026. doi:10.64898/2026.04.13.26350634.
BibTeX
@unpublished{fatemeh2026Proteo,
title = {Proteomic Age Acceleration in Multiple Sclerosis Precedes Symptom Onset and Associates with Severity},
author = {Fatemeh Siavoshi and Julián Candia and Dimitrios C. Ladakis and Blake E. Dewey and Angeliki G. Filippatou and Matthew D. Smith and Elias S. Sotirchos and Shiv Saidha and Jerry L. Prince and Ahmed Abdelhak and Ellen M. Mowry and Peter A. Calabresi and Keenan A. Walker and Kathryn C. Fitzgerald and Pavan Bhargava},
journal = {medRxiv},
year = {2026},
doi = {10.64898/2026.04.13.26350634},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Journal of Investigative Dermatology 2026
Citation only
Comparative Transcriptomic and Proteomic Profiling of Atopic Dermatitis Across Age Groups and Disease Severity Reveals Distinct Inflammatory Signatures
Epigenetics & Chromatin 2025
Open access · CC-BY
Assessment of relationships between epigenetic age acceleration and multiple sclerosis: a bidirectional mendelian randomization study
Aging 2026
Open access · CC-BY
Association of epigenetic age acceleration with MRI biomarkers of aging and Alzheimer’s disease neurodegeneration
Movement Disorders 2019
Citation only
Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alpha‐Synuclein Profiles
Journal of Translational Genetics and Genomics 2025
Open access · CC-BY
The causal relationship between epigenetic aging and osteoporosis: a bi-directional Mendelian randomization study
Frontiers in Medicine 2021
Open access · CC-BY